Author:
Ban Eunmi,Park Ji-Youn,Kim Hyung Tae,Kim Chong-Kook
Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,Drug Discovery,Molecular Medicine
Reference21 articles.
1. Al Deeb, S. K., Hamdan, I. I., and Al Najjar, S. M., Spectroscopic and HPLC methods for the determination of alendronate in tablets and urine. Talanta, 64, 695–702 (2004).
2. Hosking, D., Chilvers, C. E., Christiansen, C., Ravn, P., Wasnich, R., Ross, P., McClung, M., Balske, A., Thompson, D., Daley, M., and Yates, A. J., Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N. Engl. J. Med., 338, 485–492 (1998).
3. Hyldstrup, L., Flesch, G., and Hauffe, S. A., Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif. Tissue Int., 53, 297–300 (1993).
4. Kang, H. S., Hwang, S. J., Kim, C. K., and Park, J. S., HPLC method validation and pharmacokinetic study of alendronate sodium in human urine with fluorescence detection. J. Liq. Chromatogr. Relat. Technol., 29, 1589–1600 (2006).
5. Lin, J. H., Duggan, D. E., Chen, I. W., and Ellsworth, R. L., Physiological disposition of alendronate, a potent antiosteolytic bisphosphonate, in laboratory animals. Drug Metab. Dispos., 19, 926–932 (1991).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献